Targeting PIM2 improves antitumor immunity through promoting effector function and persistence of CD8 T cells
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci192928 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Yongxia Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology & Immunology and. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Protein Serine-Threonine Kinases, Proto-Oncogene Proteins, Neoplasm Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
The PIM kinase family is critically involved in tumorigenesis, yet its role in primary T cells is understudied. We reported that PIM2, distinct from the other 2 isoforms, inhibits T cell responses to alloantigen. Here, we further established PIM2 as a key negative regulator in antitumor immunity. Pim2 deficiency in tumor antigen–specific or polyclonal T cells enhanced their ability to control tumor growth in murine breast cancer, melanoma, and leukemia models. Pim2 deficiency enhanced cytokine production and metabolic activities in tumor-infiltrating CD8 T cells. Pim2 deficiency increased TCF1 expression and memory-like phenotype in CD8 T cells from lymphoid organs. Mechanistically, PIM2 facilitated LC3 lipidation, P62 degradation, and autophagic flux in T cells, leading to impaired glycolysis and effector cytokine production. Furthermore, through modulating VPRBP kinase phosphorylation, PIM2 inhibited histone methyltransferase activity of EZH2 in CD8 T cells, causing disrupted memory-like phenotype. Notably, the PIM2 inhibitor JP11646 markedly enhanced antitumor T cell response. The immunosuppressive role of PIM2 was validated in human T cells, where inhibition of PIM2 enhanced antitumor responses in engineered human T cells, including melanoma-specific TCR T cells and CD19 CAR T cells. Collectively, PIM2 represents a promising target for improving cancer immunotherapy through enhancing effector differentiation and persistence of CD8 T cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology & Immunology and.
- The Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- School of Medicine, Northwestern University, Chicago, Illinois, USA.
- Department of Surgery, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA.
- Department of Cell and Molecular Pharmacology and.
- Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Förderung
- National Institutes of Health
Zitieren
APA
Wu, Y., Tian, L., Pugel, A., Alimohammadi, R., Cheng, Q., Cui, W., Nishimura, M. I., Ball, L. E., Lin, C. W., Mehrotra, S., Kraft, A. S., & Yu, X. Z. (2026). Targeting PIM2 improves antitumor immunity through promoting effector function and persistence of CD8 T cells. Journal of Clinical Investigation. https://doi.org/10.1172/jci192928
Vancouver
Wu Y, Tian L, Pugel A, Alimohammadi R, Cheng Q, Cui W, et al. Targeting PIM2 improves antitumor immunity through promoting effector function and persistence of CD8 T cells. Journal of Clinical Investigation. 2026. doi:10.1172/jci192928
BibTeX
@article{Wu2026,
author = {Wu, Yongxia and Tian, Linlu and Pugel, Allison and Alimohammadi, Reza and Cheng, Qiao and Cui, Weiguo and Nishimura, Michael I and Ball, Lauren E and Lin, Chien-Wei and Mehrotra, Shikhar and Kraft, Andrew S and Yu, Xue-Zhong},
title = {Targeting PIM2 improves antitumor immunity through promoting effector function and persistence of CD8 T cells},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci192928}
}
EUVIMED